Advaxis Inc., a biotechnology company specializing in cancer immunotherapies, announced it has expanded its relationship with the GRU Cancer Center by entering into a master clinical trial agreement. Under the terms of the agreement, the Cancer Center will conduct four Phase 1/2 clinical trials under the supervision of Cancer Center Director Dr. Samir N. Khleif.
The planned trials will further develop Advaxis’ two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer.
“The preclinical success we have had with the Advaxis platform technology has prompted us to move into human trials with multiple treatment approaches for cervical and breast cancer,” Khleif said. “We hope to see positive results in cervical and breast cancer patients as we partner with Advaxis in developing its novel treatments.”
The GRU Cancer Center is a multi-disciplinary academic cancer center focused on both research and clinical treatment. Its patient-centered approach to treatment includes first-in-the-nation treatment protocols, an experimental therapeutics program that includes specialized clinics for Phase I trials and immunotherapy and a variety of ancillary programs – including nutritional and genetic counseling – designed with holistic healing in mind.